Bi biotechnology company developing hepatocyte transplantation and engineered liver-cell therapies for severe liver disease, including diseases of acquired and genetic origin
Bi biotechnology company developing hepatocyte transplantation and engineered liver-cell therapies for severe liver disease, including diseases of acquired and genetic origin. Its proprietary cell therapy platform aims to address the supply constraints that have limited liver-cell transplantation; its lead program was AMI-918. Ambys’ intellectual property assets were acquired by Cytotheryx.